Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 7/20 | 0.40 |
| ▸ | ITK | Q08881 | 7/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18369564 | 0.84 | MET (0.45) | METBTKITKCLK1DYRK1A | |
| SCHEMBL25111074 | 0.80 | POLB (0.37) | BRD4CLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL14678114 | 0.79 | AXL (0.43) | ITKBRD4CLK1DYRK1ACCNT1 | |
| SCHEMBL1885317 | 0.79 | BRD4 (0.43) | BRD4CLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL19841349 | 0.79 | CYP3A4 (0.44) | AGBL2BRD4CLK1DYRK1ACCNT1 | |
| SCHEMBL20371786 | 0.79 | PRMT5 (0.40) | BRD4CLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL14041214 | 0.77 | MET (0.43) | METBTKITKPRMT5WDR77 | |
| SCHEMBL15245298 | 0.77 | METAP2 (0.55) | METCYP1A2 | |
| SCHEMBL7921128 | 0.76 | MET (0.46) | METBTKITKPRMT5WDR77 | |
| SCHEMBL1714153 | 0.76 | KMT2A (0.47) | BRD4CLK1DYRK1ACCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| WO-2017133667-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-11 | — | — | US | disclosed |
| WO-2015050505-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | MAPKAPK2, CAMKK2, MKNK2 | MET 1482/4885AGBL2 2488/4885BTK 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.